Treatment of mucocutaneous herpes simplex infections.
D000212:Acyclovir / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003561:Cytarabine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006558:Herpes Genitalis / Q000628:therapy*; D006561:Herpes Simplex / Q000628:therapy*; D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D007978:Levamisole / Q000627:therapeutic use; D008239:Lysine / Q000627:therapeutic use; D008297:Male; D010166:Palliative Care; D010778:Photochemotherapy; D012254:Ribavirin / Q000627:therapeutic use; D018139:Simplexvirus / Q000276:immunology; D013283:Stomatitis, Herpetic / Q000628:therapy*; D014271:Trifluridine / Q000627:therapeutic use; D014467:Ultraviolet Therapy; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014765:Viral Vaccines / Q000627:therapeutic use
D000998:Antiviral Agents; D014765:Viral Vaccines; D003561:Cytarabine; D007978:Levamisole; C020235:brivudine; D001086:Arabinofuranosyluracil; C026023:fiacitabine; D012254:Ribavirin; D007372:Interferons; D014740:Vidarabine; D001973:Bromodeoxyuridine; C034935:clevudine; D008239:Lysine; D007065:Idoxuridine; D014271:Trifluridine; D000212:Acyclovir